Sign in
Taking people in United StatesPhase 4

Zopa Retreatment and Vector Shedding in Adults With RRP

Key facts

Who runs it
Precigen, Inc
Where
Atlanta, Bethesda, and Cincinnati, United StatesSee the 3 sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
30 people, planned
Started
11 Jul 2024
Expected to end
2 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Zopapogene imadenovec (Zopa)
Record updated
15 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18 years and older
  • Clinical diagnosis of recurrent respiratory papillomatosis with histological confirmation of papilloma
  • Cohort 1: Treatment-naïve with respect to Zopa
  • Cohort 2: Received a minimum of four administrations of Zopa at 5 × 10\^11 PU per injection and require clinically indicated debulking procedures
  • Presence of laryngotracheal papillomas accessible for endoscopic cleanout
  • ECOG performance status 0 or 1
  • Sexually active participants of reproductive potential must agree to use contraception during treatment and for 120 days for males and 6 months for females after last dose
  • Ability to understand and sign informed consent

Who cannot take part

  • Systemic corticosteroids >10 mg prednisone equivalent or other immunosuppressive medications within 14 days prior to dosing
  • Other systemic RRP treatments or investigational agents within 30 days
  • Conditions or therapies that increase risk or interfere with participation per investigator judgment
  • History of heparin-induced thrombocytopenia or vaccine-induced thrombotic thrombocytopenia
  • Active uncontrolled HIV, hepatitis B, or hepatitis C infection
  • Known allergy to any study drug component
  • Pregnant or nursing women

This trial is currently available in United States.

  • Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Mosope Oyewole, CRCTaking people
  • National Institute Of HealthBethesda, United StatesContact: Shannon Householder, RNTaking people
  • University of CincinnatiCincinnati, United StatesContact: Rebecca ReinertTaking people

About the trial

What the trial wants to find out

This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.

The 2 groups in the trial

  • Cohort 1 Vector SheddingTreatment being tested

    Zopa administered subcutaneously at 5 × 10\^11 particle units on Day 1, Week 2, Week 6, and Week 12. Samples for vector shedding to be collected from urine, feces, skin, and nasal tissue.

    Treatment: Zopapogene imadenovec (Zopa)

  • Cohort 2 RetreatmentTreatment being tested

    Patients with prior treatment with Zopa (5 × 10\^11 PU per injection) and require clinically indicated debulking procedure

    Treatment: Zopapogene imadenovec (Zopa)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients With Recurrent Respiratory Papillomatosis
Record updated
15 December 2025